Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 Shares

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman sold 1,270 shares of the stock in a transaction on Monday, April 15th. The stock was sold at an average price of $19.99, for a total transaction of $25,387.30. Following the transaction, the director now owns 137,155 shares of the company’s stock, valued at approximately $2,741,728.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Enliven Therapeutics Stock Performance

ELVN traded down $1.14 on Monday, reaching $19.94. The company had a trading volume of 745,161 shares, compared to its average volume of 218,023. Enliven Therapeutics, Inc. has a fifty-two week low of $9.80 and a fifty-two week high of $26.00. The company’s fifty day moving average is $16.77 and its 200 day moving average is $14.21. The stock has a market cap of $821.53 million, a P/E ratio of -9.03 and a beta of 1.06.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, March 14th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.09. On average, sell-side analysts expect that Enliven Therapeutics, Inc. will post -2.16 EPS for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ELVN. AJOVista LLC bought a new stake in shares of Enliven Therapeutics during the 4th quarter valued at about $28,000. Tower Research Capital LLC TRC bought a new position in shares of Enliven Therapeutics in the first quarter worth $36,000. Ameritas Investment Partners Inc. purchased a new position in Enliven Therapeutics during the second quarter worth about $39,000. Royal Bank of Canada boosted its holdings in shares of Enliven Therapeutics by 532.7% in the 2nd quarter. Royal Bank of Canada now owns 3,075 shares of the company’s stock worth $63,000 after purchasing an additional 2,589 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in Enliven Therapeutics during the 4th quarter worth approximately $66,000. Institutional investors own 95.08% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Mizuho assumed coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They set a “buy” rating and a $34.00 price target for the company.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.